Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose VAY736 versus placebo in primary Sjögren's syndrome
2013-000250-22Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing VAY736 with Placebo (2 arms). Primary endpoint: Change in modified EULAR Sjögren's Syndrome Disease Activity Index at week 12. Started Oct 2013; status: completed.
02
Drugs
ianalumab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2013-000250-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000250-22.